|
|
参麦注射液治疗气阴两虚型慢性心力衰竭的临床研究
|
Abstract:
目的：评价参麦注射液治疗气阴两虚型慢性心力衰竭的临床效果。方法：慢性心力衰竭患者60例采用随机数字表法随机分为两组，对照组采用常规西药治疗，试验组在对照组用药基础上加用参麦注射液，干预治疗4周，对治疗后两组心功能疗效、临床症状及LVEF、NT-proBNP、6MWD水平改善情况进行比较。结果：试验组有效率93.10%，对照组有效率75.86%，两组疗效差异有统计学意义(P < 0.05)；两组中医证候积分治疗后均较治疗前明显改善，差异有统计学意义(P < 0.05)。试验组的改善程度优于对照组，差异有统计学意义(P < 0.05)；且两组患者治疗后，LVEF、NT-proBNP、6MWD水平较前明显改善(P < 0.05)，且试验组改善程度优于对照组，差异具有统计学意义(P < 0.05)。结论：参麦注射液治疗气阴两虚型慢性心力衰竭疗效确切，值得推广。
Objective: To evaluate the clinical effect of Shenmai injection in the treatment of chronic heart failure with deficiency of both qi and yin. Method: 60 patients with chronic heart failure were randomly divided into two groups by random number table method. The control group was treated with conventional western medicine, and the experimental group was treated with Shenmai injection on the basis of the control group. Intervention treatment was performed for 4 weeks. The efficacy of cardiac function, clinical symptoms and the improvement of LVEF, NT-proBNP and 6MWD levels were compared between the two groups. Results: The effective rate of the experimental group was 93.10%, and the effective rate of the control group was 75.86%. The difference in efficacy between the two groups was statistically significant (P < 0.05); the scores of TCM syndromes in the two groups were significantly improved after treatment compared with before treatment, and the difference was statistically significant (P < 0.05). The improvement of the test group was better than that of the control group, and the difference was statistically significant (P < 0.05); and after treatment, the levels of LVEF, NT-proBNP, and 6MWD in the two groups were significantly improved (P < 0.05), and the improvement degree of the test group was better than that of the control group, and the difference was statistically significant (P < 0.05). Conclusion: Shenmai injection is effective in treating chronic heart failure with deficiency of both qi and yin, and it is worthy of promotion.
| [1] | Ramani, G.V., Vber, P.A., Mehra, M.R., et al. (2010) Chronic Heart Failure: Contemporary Diagnosis and Management. Mayo Clinic Proceedings, 85, 180-195. https://doi.org/10.4065/mcp.2009.0494 |
| [2] | 李莹莹, 王华, 杨杰孚, 等. 2017年心力衰竭领域进展[J]. 中华医学信息导报, 2018, 33(6): 19. |
| [3] | 李绍敏, 彭根兴. 中医药治疗慢性心衰临床研究现状调查[J]. 浙江中西医结合杂志, 2012, 22(4): 327-328. |
| [4] | 中华医学会心血管病分会, 中华心血管杂志编辑委员会. 慢性心力衰竭诊断治疗指南[J]. 中华心血管病杂志, 2014, 42(2): 1-25. |
| [5] | 亓鹏, 张朝香. ACC/AHA2009成人心力衰竭诊断与治疗最新指南简介[J]. 中华保健医学杂志, 2010, 12(4): 323-325. |
| [6] | Zipes, D.P., Libby, P., Bonow, R.O., et al. Braunwald心脏病学[M]. 第7版. 陈灏珠, 主译. 北京: 人民卫生出版社, 1999: 407. |
| [7] | 中国中西医结合学会心血管疾病专业委员会, 中国医师协会中西医结合医师分会心血管病学专家委员会. 慢性心力衰竭中西医结合诊疗专家共识[J]. 心脑血管病防治, 2016, 16(5): 340-346. |
| [8] | 郑筱萸. 中药新药临床研究指导原则(试行) [M]. 北京: 中国医药科技出版社, 2002. |
| [9] | ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS Statement: Guidelines for the Six-Minute Walk Test. American Journal of Respiratory and Critical Care Medicine, 166, 111-117.
https://doi.org/10.1164/ajrccm.166.1.at1102 |
| [10] | 许顶立, 白煜佳. 2017 ACC/AHA/HFSA心力衰竭管理指南更新解读[J]. 中国全科医学, 2017, 20(29): 3579-3583. |
| [11] | 耿冲, 安冬青, 谢冲, 等. 益气温阳、活血利水法联合西药与常规西药治疗慢性心力衰竭临床疗效比较的Meta 分析[J]. 中国全科医学, 2015, 18(2): 180-183. |
| [12] | 张朝霞. 疏血通联合参麦注射液对老年急性ST段抬高型心肌梗死患者经皮冠状动脉介入治疗后再灌注损伤的预防作用[J]. 实用心脑肺血管病杂志, 2017, 25(1): 84-86. |
